NCT02704390已完成3 期
An Extension Study to Evaluate the Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 3
- 主要终点
- SNAP-IV teacher form scores in ORADUR®-Methylphenidate
研究概览
简要总结
The purpose of this study is to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
详细描述
In order to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD, subjects who participated in the previous OP-2PN012-301 study will be invited to join this extension study for 24-month follow-up. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects previously enrolled in OP-2PN012-301 study and completed 4-week study treatment
- •Both subjects and parents/guardians have provided their signed and dated informed consent form for the study
排除标准
- •Subjects who experienced unmanageable adverse events (AEs) after receiving ORADUR®-Methylphenidate
- •Subjects are taking a concomitant medication (ex: Monoamine Oxidase Inhibitor (MAOI) or other ADHD treatments) that is likely to interfere with safe administration of methylphenidate within 14 day prior to the study treatment initiation
- •Subjects are joining other clinical studies and receiving any other investigational medical products within 14 days prior to the study treatment initiation.
- •By the investigators' discretion, subjects with serious or unstable medical illness that will interfere with the evaluations of study efficacy and safety
- •By the investigators' discretion, subjects cannot understand or follow the instructions given in the study
- •Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
研究组 & 干预措施
ORADUR®-Methylphenidate
Experimental
ORADUR®-Methylphenidate oral capsule will be administered once daily in the morning for 24 months.
干预措施: ORADUR®-Methylphenidate (Drug)
结局指标
主要结局
SNAP-IV teacher form scores in ORADUR®-Methylphenidate
时间窗: 24 months
Change from baseline of Swanson, Nolan, and Pelham-IV (SNAP-IV) teacher form scores
次要结局
- SNAP-IV parent form scores in ORADUR®-Methylphenidate(24 months)
- Conners' Continuous Performance Test (CPT-II) performance in ORADUR®-Methylphenidate(24 months)
- Clinical Global Impression-ADHD-Improvement (CGI-I) scores in ORADUR®-Methylphenidate(24 months)
- Diagnostic & Statistical Manual for Mental Disorders-Fifth Edition (DSM-5) diagnosis in ORADUR®-Methylphenidate(24 months)
- Treatment compliance in ORADUR®-Methylphenidate(24 months)
- Remission rate in ORADUR®-Methylphenidate(24 months)
- Clinical Global Impression-ADHD-Severity (CGI-S) scores in ORADUR®-Methylphenidate(24 months)
- Computerized Cambridge Neuropsychological Test Automated Battery (CANTAB) performance in ORADUR®-Methylphenidate(24 months)
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
3 期
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraPolycythemia VeraNCT06033586Protagonist Therapeutics, Inc.46
已完成
3 期
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity DisorderAttention Deficit/Hyperactivity DisorderNCT01338818Novartis Pharmaceuticals299
已完成
3 期
Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.Urinary Bladder, NeurogenicNCT02501928Pfizer12
已完成
3 期
Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult SubjectsPsoriasisNCT00111436Amgen912
已完成
3 期
A Long-Term Safety Study to Evaluate Methylphenidate HCL Tablets at Multiple Dose Levels in Adults With Attention Deficit Hyperactivity DisorderAttention Deficit Hyperactivity DisorderNCT00326300McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.560